Gilead's remdesivir trial ahead of schedule

来源: cn_abcd 2020-04-24 14:11:02 [] [旧帖] [给我悄悄话] 本文已被阅读: 次 (2897 bytes)

A key U.S. governmental trial for Gilead's (GILD +1.8%) remdesivir, could report results as early as mid-May, lead researcher Dr. Andre Kalil tells Reuters.

Preliminary findings could come even sooner for the randomized trial, which was launched in February by the National Institute of Allergy and Infectious Diseases.

Enrollment in the trial closed Sunday and exceeded its goal of 400-500 patients. The trial is designed to show whether the antiviral can improve outcomes like hospitalization length and survival for patients with a range of COVID-19 severity.

Doctors at Houston Methodist Hospital say they've treated 41 mostly severely ill COIVD-19 patients since March 23 - none have died and half have returned home.

Related: Yesterday, the WHO mistakenly posted draft documents of a Chinese study that showed remdesivir failed to improve patients' conditions. Gilead countered that the study was underpowered for efficience since it was terminated early for low enrollment.

所有跟帖: 

good sign -X-RAY- 给 X-RAY 发送悄悄话 X-RAY 的博客首页 (0 bytes) () 04/24/2020 postreply 14:21:21

请您先登陆,再发跟帖!

发现Adblock插件

如要继续浏览
请支持本站 请务必在本站关闭/移除任何Adblock

关闭Adblock后 请点击

请参考如何关闭Adblock/Adblock plus

安装Adblock plus用户请点击浏览器图标
选择“Disable on www.wenxuecity.com”

安装Adblock用户请点击图标
选择“don't run on pages on this domain”